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placebo controlled trial
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Dunger, professor of paediatrics,6 Malcolm D C Donaldson, senior lecturer in child health1 on behalf of the
British Society for Paediatric Endocrinology and Diabetes
ABSTRACT
Objective To examine the effect of oxandrolone and the
timing of pubertal induction on final height in girls with
Turner’s syndrome receiving a standard dose of growth
hormone.
Design Randomised, double blind, placebo controlled
trial.
Setting 36 paediatric endocrinology departments in UK
hospitals.
ParticipantsGirls with Turner’s syndrome aged 7-13 years
at recruitment, receiving recombinant growth hormone
therapy (10 mg/m2/week).
Interventions Participants were randomised to
oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or
placebo from 9 years of age. Those with evidence of
ovarian failure at 12 years were further randomised to oral
ethinylestradiol (year 1, 2 µg daily; year 2, 4 μg daily; year
3, 4 months each of 6, 8, and 10 μg daily) or placebo;
participants who received placebo and those recruited
after the age of 12.25 years started ethinylestradiol at age
14.
Main outcome measure Final height.
Results 106 participants were recruited, of whom 14
withdrew and 82/92 reached final height. Both
oxandrolone and late pubertal induction increased final
height: by 4.6 (95% confidence interval 1.9 to 7.2) cm
(P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm
(P=0.05, n=48) for late pubertal induction with
ethinylestradiol. In the 48 children who were randomised
twice, the effects on final height (compared with placebo
and early induction of puberty) of oxandrolone alone, late
induction alone, and oxandrolone plus late induction
were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No
cases of virilisation were reported.
Conclusion Oxandrolone had a positive effect on final
height in girls with Turner’s syndrome treated with growth
hormone, as did late pubertal induction with
ethinylestradiol at age 14 years. However, these effects
were not additive, so using both had no advantage.
Oxandrolone could, therefore, be offered as an alternative
to late pubertal induction for increasing final height in
Turner’s syndrome.
Trial registration Current Controlled Trials
ISRCTN50343149.
INTRODUCTION
Turner’s syndrome can be defined as absence or
abnormality of the second X chromosome in a major
cell line in a phenotypic female. The phenotype is
highly variable, but short stature and gonadal dysgen-
esis are usually present. Short stature in Turner’s syn-
drome relates to impairment of each phase of the
infancy-childhood-puberty model of growth,1 and it
results in a mean untreated final height approximately
21 cm below that of the unaffected female population.2
Themainstay of treatment for short stature is recombi-
nant growth hormone, available since 1985 and
licensed for use in Turner’s syndrome. Studies have
shown its efficacy in improving height velocity and
final height, although individual outcomes vary
markedly.3-10
The adjunctive use in Turner’s syndrome of the ana-
bolic steroid oxandrolone remains controversial.
When given in combination with growth hormone
treatment, some studies have reported improved final
height,6 11 12 whereas others have reported little or no
effect.13-15 The high doses used in early studies were
associated with virilisation,612 14 and even low doses,
as reported in a recent Dutch publication, may be
problematic.15 These potential adverse effects must
be balanced against potential improvement in growth.
Most girls with Turner’s syndrome need oestrogen
therapy during adolescence to induce pubertal
development.16 However, the optimal age at which to
begin remains controversial; some people advocate a
delay to extend the growth period and increase final
height,5 6 17 18 whereas others have highlighted psycho-
logical problems of delaying pubertal development,
suggesting that the benefits are marginal.19 The British
Society for Paediatric Endocrinology and Diabetes
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recognised the uncertainties relating to the use of oxan-
drolone and timing of pubertal induction and set up the
UK Turner Study in 1999 to investigate them.
METHODS
Participants
Members of the British Society for Paediatric Endo-
crinology andDiabetes recruited patients from partici-
pating paediatric endocrinology departments in UK
hospitals. Inclusion criteria for participation of patients
were karyotype confirmed Turner’s syndrome (all
karyotypes were eligible, including mosaic), age
7-13 years, no previous growth hormone treatment or
previous treatment in the range 8.3-11.7 mg/m2/week
in five to seven injections aweek, noprevious oxandro-
lone and oestrogen therapy, and open epiphyses.
Exclusion criteria were major systemic illness that
might affect growth and social or psychological diffi-
culties likely to seriously impair concordance.
Study design
Wedevised a double blind, placebo controlled, rando-
mised controlled trial, including two randomisations in
a two by two factorial design. Figure 1 shows the flow
chart of the design and participants. A steering com-
mittee (British Society for Paediatric Endocrinology
and Diabetes Clinical Trials/Audit Group) supervised
the study, and an independent data and safetymonitor-
ing group was established. All participants’ parents
gave written informed consent.
Randomisation and masking
The British Society for Paediatric Endocrinology and
Diabetes Clinical Trials Unit (Cambridge, UK) used
minimisation by weighted randomisation for the
study’s two randomisations.20 Randomisation 1, to
oxandrolone or placebo, took place at age 9 years (or
at enrolment, if older) and was balanced for enrolling
centre, quarter of mid-parental height, and previous
exposure to growth hormone treatment. Randomisa-
tion 2 took place at age 12 years in girls with ovarian
failure (basal serum follicle stimulating hormone con-
centration >10 U/L), with additional minimisation for
randomisation 1, to begin oral ethinylestradiol or pla-
cebo at 12 years; the placebo group subsequently
started ethinylestradiol at 14 years. Girls with a follicle
stimulating hormone concentration below 10U/L and
a karyotype associated with preservation of ovarian
function (45,X/46,XX and 45,X/47,XXX21) (the spon-
taneous puberty group) were not randomised at rando-
misation 2. Girls with other karyotypes were tested for
concentrations of gonadotrophin releasing hormone
and were randomised at randomisation 2 if the peak
follicle stimulating hormone concentration was above
30 U/L. Participants enrolled after the age of 12.
25 years and without spontaneous puberty (the late
group) started ethinylestradiol at 14 years.
Treatment
All participants received the growth hormone prepara-
tion of their choice at 10 mg/m2/week in daily subcuta-
neous injections. Oral oxandrolone (SPA, Milan, Italy)
was given at 0.05 mg/kg/day, with a maximum daily
dose of 2.5 mg. Oral ethinylestradiol (UCB Pharma,
Slough, UK) was given daily as follows, regardless of
the age at starting: year 1, 2 μg; year 2, 4 μg; year 3,
four months each of 6, 8, and 10 μg. The code for ran-
domisation 2 was broken at 15 years to allow introduc-
tion of progesterone therapy: oral norethisterone
(CP Pharmaceuticals, Wrexham, UK) 5 mg daily for
five days each month.
Treatment with growth hormone and oxandrolone
continued until final height was reached. Oestrogen/
Recruited (n=106)
Randomisation 1 (n=106)
Randomisation 2 (n=60)
Withdrawn* (n=7)
Withdrawn‡ (n=7)
Still growing (n=10)
Maximum height
Randomisation 1 (n=92)
Randomisation 1+2 (n=56)
n=3
n=1
n=4
Oestrogen at
12 years (n=17)
Oestrogen at
14 years (n=17)
Oestrogen at
12 years (n=12)
Oestrogen at
14 years (n=14)
Late group†
(n=11)
Spontaneous
puberty (n=7)
Late group†
(n=10)
n=9
n=1
n=10
n=1
n=11
n=1
n=13
n=9
n=1
n=9 n=11
n=3 n=3
n=10
n=17
n=2
n=15
n=1
n=10 n=7
n=14
n=2
n=13 n=10
n=1
n=6
Spontaneous
puberty (n=11)
Oxandrolone (n=51) Placebo (n=55)
Final height
Randomisation 1 (n=82)
Randomisation 1+2 (n=48)
Fig 1 | Flow chart of participation in UK Turner Study according to treatment groups, completions, and withdrawals. *Withdrawn before 12 years of age (that is,
randomised only at randomisation 1 to oxandrolone or placebo). †Aged ≥12.25 years at recruitment; oestrogen treatment started at 14 years with no
randomisation. ‡Withdrawn after 12 years of age (that is, randomised at randomisation 1 to oxandrolone or placebo and at randomisation 2 if oestrogen
treatment needed)
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progesterone therapy continued at an adult replace-
ment dose once pubertal induction was completed.
White, uncoated, flat bevelled edge placebo tablets
(7 and 5mm in diameter) (Essential Nutrition, Brough,
UK) were specially manufactured to match the size,
weight, and appearance of oxandrolone 2.5 mg and
ethinylestradiol 2 µg tablets respectively. The study’s
central pharmacy (Royal Hospital for Sick Children,
Glasgow, UK) supplied all tablets in a double blind,
placebo controlled fashion; only staff at the British
Society for Paediatric Endocrinology and Diabetes
Clinical Trials Unit and the central distributing phar-
macy were not blinded to treatment allocations.
Oxandrolone supplies
In 2004 and 2008, the sole European manufacturer of
oxandrolone 2.5mg ceased production, resulting in 34
participants in 2004 and 11 in 2008 temporarily sus-
pending active oxandrolone treatment (mean dura-
tion: 2004, 52 days; 2008, 163 days). In 2008, the
decision was taken to terminate the treatment arm
forthwith, resulting in eight participants stopping
oxandrolone treatment prematurely.
Study procedures
At clinic visits every four to six months, height was
measured with a Harpenden stadiometer to the last
completed 1 mm and converted to an SD score by
using the British 1990 reference.22 Radiographs of the
left wrist were obtained annually, and a single observer
(WFP) analysed them for bone age estimation accord-
ing to the Tanner Whitehouse II method.23 Biochem-
ical analyses followed local protocols, and the results
were reported centrally.
Standardised pharmacovigilance procedures were
followed, with recording of adverse events or reactions
at each visit and subsequent review by the Data and
Safety Monitoring Group. Data collection ceased if
participants withdrew consent, although we included
previously collected data in the analysis.
Statistical methods
The primary outcome was final height, defined as
height velocity less than 1 cm/year and bone age at
least 15.5 years. Secondary outcomes were maximum
height (that is, the most recently available height), age
of attaining final height, and the three summary growth
parameters from the SITAR analysis described below.
Assuming a standard deviation of 5 cm, we needed
50 girls in each group to detect a difference between
groups in mean final height of 2.8 cm with 80%
power at 5% significance—a total of 100 patients. The
study was not formally powered to detect a significant
interaction between the two randomisations. In the
event, more than 100 patients were recruited, but
fewer than 100 were followed up to final height.
Table 1 | Characteristics of participants at enrolment, maximum height, and final height, according to treatment group. Values are mean (SD) unless stated
otherwise
Characteristics
Randomised to
oestrogen at 12 years
Randomised to
oestrogen at 14 years
Late group (oestrogen at
14 years) No oestrogen needed
TotalOxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo
At enrolment* (n=12) (n=17) (n=14) (n=17) (n=10) (n=11) (n=11) (n=7) (n=99)
Median (range) age
at diagnosis (years)
0.1 (0-9.8) 4.6 (0-9.2)† 4.5 (0-9.8) 1.5 (0-9.8) 2.8 (0-12.7) 3.1 (0-13.4) 6.6 (0.7-10.4) 8.3 (0.5-10.1) 3.8 (0-13.4)
Age (years) 10.1 (1.3) 9.4 (0.7) 9.5 (1.4) 9.7 (1.2) 12.5 (0.4) 12.8 (0.4) 9.8 (1.1) 9.8 (1.4) 10.3 (1.6)
Height (cm) 126.4 (6.9) 120.5 (5.9) 121.6 (6.7) 125.7 (6.7) 137.2 (6.8) 133.9 (4.2) 124.4 (7.4) 125 (9.2) 126.2 (8.3)
Height SD score −1.9 (0.7) −2.4 (0.8) −2.2 (0.8) −1.8 (0.8) −2.1 (0.9) −2.9 (0.6) −2.1 (0.9) −2.0 (0.8) −2.1 (0.8)
Target height (cm) 163.8 (3.4) 162.0 (4.0) 161.5 (4.1) 163.1 (5.5) 165.1 (2.6) 161.6 (2.9) 163.0 (4.7) 162.6 (4.5) 162.7 (4.1)
Median (range) age
at growth hormone start
(years)
5.4 (4.0-10.2) 7.3 (2.4-10.1) 6.1 (2.2-10.5) 4.2 (2.4-9.6) 8.3 (4.5-12.8) 9.5 (4.0-13.8) 6.0 (3.2-10.9) 8.7 (1.7-10.3) 6.4 (1.7-13.8)
Median (range) duration of
growth hormone before
oestrogen induction (years)
6.6 (1.8-8.0) 4.7 (1.9-9.6) 7.9 (3.5-11.9) 9.8 (4.4-11.6) 5.7 (1.2-9.5) 4.5 (0.2-10.0) – – 6.6 (0.2-11.9)
At maximum height‡ (n=11) (n=17) (n=13) (n=15) (n=9) (n=10) (n=10) (n=7) (n=92)
Age (years) 16.2 (1.4) 15.9 (1.2) 16.2 (1.5) 16.8 (1.0) 17.0 (1.0) 17.9 (1.0) 14.9 (0.8) 15.0 (0.9) 16.3 (1.4)
Height (cm) 154.4 (3.9) 147.2 (7.0) 153.0 (8.1) 152.0 (6.8) 155.3 (4.3) 148.9 (6.0) 151.9 (6.0) 150.2 (6.2) 151.4 (6.7)
Height SD score −1.4 (0.7) −2.5 (1.2) −1.5 (1.1) −1.9 (1.1) −1.3 (0.7) −2.4 (1.0) −1.5 (1.0) −1.8 (0.9) −1.8 (1.1)
Change in height SD score 0.6 (0.5) −0.1 ( 0.6) 0.7 (1.0) −0.1 ( 0.7) 0.7 (0.8) 0.5 ( 0.8) 0.5 (1.0) 0.2 (0.7) 0.3 (0.8)
At final height§ (n=11) (n=14) (n=10) (n=13) (n=9) (n=10) (n=9) (n=6) (n=82)
Age (years) 16.2 (1.4) 16.2 (0.8) 16.8 (0.8) 17.2 (0.9) 17.0 (1.0) 17.9 (1.0) 15.0 (0.9) 15.2 (1.0) 16.5 (1.3)
Height (cm) 154.4 (3.9) 147.0 (7.4) 155.1 (4.1) 153.1 (6.7) 155.3 (4.3) 148.9 (6.0) 151.8 (6.4) 149.4 (6.4) 151.8 (6.4)
Height SD score −1.4 ( 0.7) −2.6 (1.2) −1.4 (0.7) −1.7 (1.1) −1.3 (0.7) −2.4 (1.0) −1.5 (1.1) −2.0 (0.9) −1.8 (1.0)
Change in height SD score 0.6 (0.5) −0.3 (0.5) 0.9 (0.9) −0.1 (0.8) 0.7 (0.8) 0.5 ( 0.8) 0.3 (1.0) 0.1 (0.9) 0.3 (0.8)
*Excluding 7 withdrawn participants: 1 immediately after enrolment, so no baseline data available; 6 before age 12, who were randomised only at randomisation 1 (4 oxandrolone, 2
placebo).
†Excluding 2 antenatal diagnoses.
‡Excluding 14 withdrawn participants (that is, including 82 at final height and 10 yet to reach final height).
§Excluding 14 withdrawn participants and 10 yet to reach final height.
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We estimated the effects of the two randomisations
separately by using multiple regression. We also
adjusted randomisation 2 (timing of pubertal induc-
tion) for randomisation 1 (oxandrolone) and tested
for an interaction.
In addition, we applied SITAR (superimposition by
translation and rotation), a novel method of growth
curve analysis, to the data.24 SITAR transforms indivi-
dual growth curves so that they become essentially the
same as each other and, when superimposed, define
the average summary curve. To achieve this, each indi-
vidual curve is suitably altered in three distinct ways:
the curve is shifted up/down (a measure of the child’s
size in cm) and left/right (ameasure of growth tempo in
years), and the age axis is stretched/squashed (a mea-
sure of percentage velocity). Size, tempo, and velocity
are thus participant specific random effects summaris-
ing how each girl’s curve differs from the average
curve. The effects of the randomisations can be
explored by comparing the values of the random
effects by trial arm. Equally, separate summary curves
can be constructed for each trial arm.
RESULTS
One hundred and six girls with Turner’s syndrome
were recruited from 36 UK hospitals between 1999
and 2003, of whom 14 withdrew (four of them because
of early organisational errors), leaving 92 to complete
the study (fig 1). The breakdown of karyotypes was 45,
X (39), 45,X/46,XX (18), 45,X/46,XrX (9), complex
mosaics containing three or more cell lines (8),
45,X/46,XiX (7), 45,X/45,XY (7), 46,XX including a
structural abnormality of second X (7), 45,X/46,XY
including a structural abnormality of Y (3), 45,X/46,XX
including a structural abnormality of second X (3),
45,X/47,XXX (2), and other (3).
All 106 participants were randomised at or after
9 years of age to oxandrolone or placebo (randomisa-
tion 1), and 60 were also randomised at 12 years to
early or late induction of puberty (randomisation 2).
Of the 46 girls not randomised at 12 years, 21 enrolled
after 12 years (the late group), 18 had spontaneous pub-
erty, and seven had withdrawn before the age of
12 years.
Final and maximum height
Table 1 shows participants’ characteristics at enrol-
ment, at maximum height, and at final height by treat-
ment group. At the time of writing, 82 participants had
attained a mean final height of 151.8 (SD 6.4) cm, and
10 others continued growing. Table 2 shows details of
final height and maximum height according to the
study’s two randomisations.
By twice randomised group, the mean final heights
were placebo/early induction 147.0 cm, placebo/late
induction 153.1 cm, oxandrolone/early induction
154.4 cm, and oxandrolone/late induction 155.1 cm
(table 1). Table 3 summarises the results of the rando-
mised comparisons. For randomisation 1, final height
was significantly greater with oxandrolone than pla-
cebo (4.6 cm, 95% confidence interval 1.9 to 7.2;
P=0.001). Similarly, for randomisation 2, final height
was significantly greater with pubertal induction at
14 years than at 12 years (3.8 cm, 0.0 to 7.5; P=0.05).
However, the positive effects of oxandrolone and
late induction were not additive. Among girls pre-
viously randomised to oxandrolone, the effect of late
induction comparedwith early inductionwas clinically
insignificant (+0.7 cm); in the placebo group, however,
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Fig 2 | Individual height growth curves according to randomisation 1: unadjusted (left) and SITAR adjusted (right)
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late induction added 6.2 cm compared with early
induction (table 3, interaction). The two treatments
together were thus no more effective than either one
alone, as shown by the substantial and close to signifi-
cant negative interaction. The mean effect on final
height of oxandrolone, late induction of puberty, or
both compared with placebo and early induction was
+7.1 cm (that is, the mean final height in the combined
oxandrolone/early, oxandrolone/late, and placebo/
late groups compared with the placebo/early group),
which is appreciably larger than the effects for either
randomisation alone (table 3, combination). This was
because the randomisation analyses compared inter-
vention and control groups in which half of each con-
trol group had received an effective intervention from
the other randomisation, thus reducing the apparent
effect size. The standard deviation for the combined
group was 5.1 cm, rather less than the 7.4 cm for the
placebo/early induction group (P=0.1), suggesting that
treatment preferentially benefited the shortest girls.
Table 3 also includes the results for maximum
height, based on the 92 girls still in the trial. The oxan-
drolone effect of +4.3 cm (P=0.002) was similar to that
for final height (+4.6 cm), and the late induction effect
of +2.4 cm (P=0.2) was appreciably smaller than the
+3.8 cm for final height. The age of attainment of
final height was similar for oxandrolone and placebo
(16.2 v 16.7 years; P=0.1) and later, by design, for late
versus early induction (16.9 v 16.1 years; P=0.009).
SITAR analysis of height curves
We applied the SITAR analysis to the 105 participants
with at least one height measurement (one girl in the
control group withdrew immediately after randomisa-
tion 1). Figure 2 shows individual height curves un-
adjusted (left panel) and SITAR adjusted with the
summary curve (right panel). The curves are labelled
according to randomisation 1, and the oxandrolone
curves tend to be above and to the left of the placebo
curves.
The SITAR adjustment process estimated the size,
tempo, and velocity parameters for each participant,
which when applied to their curves made them all
very similar, with a residual standard deviation of
0.6 mm around the summary curve (fig 2, right
panel). Comparison of the mean values of the para-
meters by trial arm showed differences in size (oxan-
drolone v placebo +2.6 cm; P=0.02) but not tempo
(−0.3 years; P=0.1), and the mean velocity was drama-
tically greater for oxandrolone (difference +23%, SE
Table 2 | Final height and maximum height data for participants randomised twice, according
to randomisation 1 (oxandrolone/placebo) and randomisation 2 (pubertal induction at 14/
12 years). Values are mean (SD)
Measurement
Randomisation 1 Randomisation 2
Oxandrolone Placebo
Induction at
14 years
Induction
at 12 years
Final height (n=39) (n=43) (n=23) (n=25)
Age (years) 16.2 (1.4) 16.7 (1.3) 16.9 (0.8) 16.1 (1.2)
Height (cm) 154.2 (4.7) 149.6 (7.0) 154.0 (5.7) 150.2 (7.1)
Height SD score −1.4 (0.7) −2.2 (1.1) −1.6 (0.9) −2.1 (1.2)
Change in height SD score 0.7 (0.8) 0.0 (0.8) 0.3 (1.0) 0.1 (0.7)
Maximum height (n=43) (n=49) (n=28) (n=28)
Age (years) 16.0 (1.4) 16.5 (1.3) 16.6 (1.2) 16.0 (1.3)
Height (cm) 153.6 (5.9) 149.3 (6.8) 152.4 (7.3) 150.0 (6.9)
Height SD score −1.4 (0.8) −2.2 (1.1) −1.7 (1.1) −2.0 (1.1)
Change in height SD score 0.6 (0.8) 0.0 (0.7) 0.3 (0.9) 0.2 (0.7)
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Fig 3 | SITAR fitted summary height curves by trial arm for randomisation 1 (left) and randomisation 2 (right)
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4%; P<0.001). This indicated that the developmental
age scale in the oxandrolone armwas foreshortened by
23%, increasing the velocity and making the oxandro-
lone curve correspondingly steeper than the placebo
curve, although the age of final height was no earlier.
This effect is seen in figure 3 (left panel), which shows
SITAR summary curves calculated separately for
oxandrolone and placebo. The two curves cross at
10 years, and height velocity is consistently greater in
the oxandrolone arm.
Figure 3 (right panel) shows the corresponding com-
parison of summary height curves for randomisation 2,
late versus early induction. The differences here were
smaller, the curves diverging only after 14 years; the
late versus early comparisons for size (+2.2 cm) and
velocity (−9%) were statistically insignificant (P>0.1),
whereas tempo was slightly delayed in the late induc-
tion arm (+0.4 years; P=0.06).
Adverse events
Between 1999 and 2009, 197 adverse events were
reported; none of them were suspected to be unex-
pected serious adverse reactions. Ten were classified
as serious adverse events, as they involved admission
to hospital for procedures including appendicectomy
and ear, nose, and throat surgery (for example, grom-
met (ventilation tube) insertion). Four adverse events
could have been related to oxandrolone or ethinyles-
tradiol: acne in a 15 year old (all study drugs were con-
tinued, and randomisation was later revealed as
oxandrolone and pubertal induction at 14 years);
persistent hypertension in a 13 year old (oxandrolone/
placebo was stopped and antihypertensive treatment
started, blood pressure normalised, and oxandro-
lone/placebo treatment was restarted; the randomisa-
tion was later revealed as oxandrolone and pubertal
induction at 12 years); abnormal liver function in a
16 year old (the participant was at near final height
and elected to stop growth promoting treatment; ran-
domisation was later revealed as oxandrolone and
pubertal induction at 14 years); and episodic “hot
flushes” in a 15 year old (all study drugs were contin-
ued; randomisation was later revealed as placebo and
pubertal induction at 14 years). No virilisation was
reported; in particular, no voice deepening or clitoro-
megaly was noted.
DISCUSSION
This randomised controlled trial of growth promoting
treatment inTurner’s syndrome showed a clear benefit
to final height of oxandrolone treatment and of intro-
ducing ethinylestradiol for pubertal induction at age 14
rather than 12 years.
Comparison with other studies
This positive effect of oxandrolone on final height
compares favourably with previous studies.5 6 11 12
Early studies using high doses of oxandrolone had to
reduce or stop treatment after reports of virilisation,6 12
and others showed little or no effect of
oxandrolone.13 14 However, they were retrospective
in design and varied in treatment protocol. In contrast,
the UK Turner Study used a prospective placebo con-
trolled design, with consistent doses of oxandrolone
throughout. A recent Dutch trial comparing growth
hormone with two doses of oxandrolone (0.03 and
0.06 mg/kg/day) reported that the lower dose signifi-
cantly increased adult “height gain” compared with
placebo, whereas the higher dose did not.15 In contrast,
the final height in both oxandrolone groups was only
approximately 1 cm greater than placebo (156.7 cm
and 156.5 cm versus 155.6 cm). The more favourable
outcome in theUK study could be related to earlier age
at starting growth hormone therapy (6.4 v ~9 years)
and also to the lower doses of oxandrolone given in
the UK study (0.05 mg/kg/day, maximum 2.5 mg
daily) compared with the 0.06 mg/kg/day arm of the
Dutch study.
No adverse events directly attributable to oxandro-
lone were reported in the UK Turner Study; in parti-
cular, no virilisation was reported. Although
Table 3 | Effects of two randomisations, their interaction, and their combination, on mean final height and mean maximum
height
Randomisation Mean/mean difference (SE) Mean/mean difference (SE) Difference (95% CI) P value
Randomisation 1 (Oxandrolone) (Placebo)
Final height (cm) 154.2 (0.8) (n=39) 149.6 (1.1) (n=43) 4.6 (1.9 to 7.2) 0.001
Maximum height (cm) 153.6 (0.9) (n=43) 149.3 (1.0) (n=49) 4.3 (1.6 to 6.9) 0.002
Randomisation 2 (Induction at 14 years) (Induction at 12 years)
Final height (cm) 154.0 (1.2) (n=23) 150.2 (1.4) (n=25) 3.8 (0.0 to 7.5) 0.05
Maximum height (cm) 152.4 (1.4) (n=28) 150.0 (1.3) (n=28) 2.4 (−1.5 to 6.2) 0.2
Interaction of R1 by R2* (Oxandrolone
(14 years−12 years))
(Placebo (14 years−12 years))
Final height (cm) 0.7 (1.7) (n=21) 6.2 (2.7) (n=27) −5.5 (−12.4 to 1.4) 0.1
Maximum height (cm) −1.5 (2.5) (n=24) 4.7 (2.5) (n=32) −6.2 (−13.5 to 1.2) 0.1
Combination of R1 and R2† (Oxandrolone OR 14 years) (Placebo AND 12 years)
Final height (cm) 154.1 (0.9) (n=34) 147.0 (2.0) (n=14) 7.1 (3.4 to 10.8) <0.001
Maximum height (cm) 153.0 (1.0) (n=39) 147.2 (1.7) (n=17) 5.8 (1.9 to 9.7) 0.004
*Summary statistics under oxandrolone and placebo are differences in mean height (SE) between corresponding 14 year and 12 year induction
groups.
†Groups: oxandrolone/12 years, oxandrolone/14 years, and placebo/14 years combined; and placebo/12 years.
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oxandrolone could have contributed to the cases of
acne, hypertension, and abnormal liver function, caus-
ality cannot be assumed as these are commonly seen in
Turner’s syndrome.25 26 By contrast, the Dutch study
reported virilisation in 15/36 girls receiving 0.06 mg/
kg/day, which was severe enough for treatment to be
discontinued in seven. However, patients receiving
placebo also reported virilisation, and how these
events were assessed is unclear.15 Furthermore, the
maximum daily dose of 2.5 mg used in the UK study
irrespective of body weight could account for the
absence of reported virilisation.
The UK Turner Study has also shown a positive
effect on final height of introducing ethinylestradiol at
age 14 rather than 12 years, consistent with the effect of
oestrogen on epiphyseal fusion and supporting pre-
vious published associations betweendelayed pubertal
induction and increased height.6 13 18 Since 1999,
however, concern has been expressed about the poten-
tial cardiovascular, skeletal, reproductive, and psycho-
logical consequences of prolonged oestrogen
deficiency.19 27-29 The finding that oxandrolone allows
timely pubertal induction is thus attractive and in keep-
ing with other work.30-34 This study shows that oxan-
drolone increases height velocity throughout the
growing period yet does not materially advance the
age of final height.
However,whereas both oxandrolone and late induc-
tion have been shown to increase final height, the two
effects were not additive, so that giving either is bene-
ficial but giving both is no better. One possible expla-
nation for this is that there is a “ceiling” for the extra
height available from growth promoting strategies in
Turner’s syndrome.
The subset of participants who were randomised
twice and received oxandrolone had a larger “gain”
in final height than did those who did not need any
oestrogen treatment, whether they received oxandro-
lone or not. The numbers were too small to allowmore
detailed analysis, but we speculate that the girls who
showed spontaneous puberty would have fused their
epiphyses earlier than the other girls, which may
have resulted in a less favourable final height.
Strengths and limitations of study
This randomised controlled trial has examined a large
cohort of patients treated systematically over a 10 year
period. Treatment has been well tolerated, such that
dropout rates were low (14/106) and the mean final
height for the group to date (151.8 cm) is well above
the target of 150 cm for girls with Turner’s syndrome
treated with growth hormone.6 35 36
The number of girls who had completed the study
and achieved final height at the time of analysis (n=82)
fell short of the target sample size of 100. Even when
the remaining girls complete the study, the number
evaluable at final height will still only be 92. Despite
this, however, the group of 82 girls has been sufficient
to show positive effects of oxandrolone and delayed
pubertal induction, and the addition of the 10 girls
yet to complete is unlikely to materially alter the out-
come. However, the failure to achieve the target sam-
ple size may have limited the ability to detect an
interaction between the two randomisations.
Unfortunately, the break in production of oxandro-
lone 2.5 mg tablets twice led to deviations from the
protocol. Placebo tablets were unavailable for other
oxandrolone preparations, and eventually the difficul-
ties in supply led to the early termination of the treat-
ment arm. Therefore, the results may underestimate
the true effect of oxandrolone. Even so, they make a
strong case for reintroduction of oxandrolone manu-
facture in Europe or, failing that, affordable importa-
tion, as costs of supplies from elsewhere are
prohibitive.
Girls with mosaic Turner’s karyotypes were
included in the study. With a larger sample size, the
effect of different karyotypes, with varying haploinsuf-
ficiency of the SHOX region, on height outcome could
be examined. However, the group sizes of those who
were randomised twice and attained final height were
too small to allow further breakdown by karyotype.
Ameasure of bonemineral density was not included
in the study protocol and would have provided valu-
able information. Although its value is now recognised
in this patient group, the necessary scanning equip-
ment was not routinely available at all participating
centres when the study started.
Conclusions and policy implications
Oxandrolone has a positive effect on final height, as
has inducing puberty at age 14 rather than 12 years.
However, doing both offers no added benefit. We
recommend, therefore, that when growth promotion
is being considered in girls with Turner’s syndrome,
families are offered oxandrolone as an alternative to
late pubertal induction.
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